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Abstract: Although the awareness and control of hypertension has increased, only 37% of 
hypertensive patients in the US achieve the conservative goal of  140/90 mmHg. Achieving 
optimal blood pressure (BP) control is the most important single issue in the management of 
hypertension, and in most hypertensive patients, it is difﬁ  cult or impossible to control BP with 
one drug. Blocking two or more BP regulatory systems provides a more effective and more 
physiologic reduction in BP, and current guidelines have recommended the use of combination 
therapy as ﬁ  rst-line treatment, or early in the management of hypertension. Fixed combination 
therapy is an efﬁ  cacious, relatively safe, and may be cost-effective method of decreasing 
BP in most patients with essential hypertension. Similar to other combinations, ﬁ  xed-dose 
combination tablets containing the dihydropyridine calcium channel blocker amlodipine and 
the angiotensin II receptor blocker olmesartan bring together two distinct and complementary 
mechanisms of action, resulting in improved BP control and potential for improved target organ 
protection relative to either class of agent alone.
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Introduction
Hypertension is a highly prevalent condition and an important modiﬁ  able risk factor 
for cardiovascular (CV) disease. Hypertension affects nearly 1 in 3 adults in the US, 
with a prevalence of 29.3% in a population  18 years old (Hajjar and Kotchen 2003; 
Ong et al 2007; Rosamond et al 2008), and as many 1.5 billion persons worldwide 
will have hypertension by 2025 (Kearney et al 2005).
Hypertension is the most common risk factor for CV death and disability in both 
developed and developing countries, and control of blood pressure (BP) signiﬁ  cantly 
reduces these risks (Turnbull et al 2003; Kearney et al 2005). Observational studies 
have shown that mortality from ischemic heart disease and stroke in persons 40–89 
years of age increases in log linear fashion with increases in both systolic (SBP) and 
diastolic BP (DBP) (Lewington et al 2002). For each increase in SBP of 20 mmHg 
or in DBP of 10 mmHg over the entire range from 115/75 mmHg, there is a twofold 
increase in mortality related to coronary artery disease and stroke.
Although the awareness and control of hypertension have increased, only 37% of 
hypertensive patients in the United States achieve the conservative goal of  140/90 mmHg 
(Ong et al 2007). Achieving optimal BP control is the most important single issue in 
the management of hypertension, and in most hypertensive patients, it is difﬁ  cult or 
impossible to control BP with one drug. For example, in the very large Antihypertensive 
and Lipid Lowering Treatment to Prevent Heart Attack (ALLHAT) trial less than Vascular Health and Risk Management 2008:4(3) 654
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30% of more than 42,000 participants achieved goal BP 
( 140/90 mmHg) on monotherapy (Cushman et al 2002). 
In the Losartan Intervention For Endpoint (LIFE) trial, in 
which treatment to goal ( 140/90 mmHg) was aggressively 
pursued in  9,000 patients with left ventricular hypertrophy 
(LVH) and an average baseline BP of 175/98 mmHg,  90% 
required more than one antihypertensive agent (Dahlöf et al 
2002). Although participants in the LIFE trial had free medi-
cations and close follow-up, only 49% of patients assigned 
to losartan and 46% assigned to atenolol achieved the BP 
goal ( 140/90 mmHg).
Based on clinical trials, current guidelines have recom-
mended the use of combination therapy as ﬁ  rst-line treatment, 
or early in the management of hypertension in patients with 
comorbidities that require prompt BP reduction. Initial treat-
ment with 2 antihypertensive agents is suggested for persons 
with BP  20/10 mmHg above goal (Figure 1) (Chobanian 
et al 2003; Mancia et al 2007).
Patient adherence
Patient adherence refers to the willingness and ability of an 
individual patient to follow health-related advice, take medi-
cation as prescribed, attend scheduled clinic appointments, 
and complete recommended tests and consultations (Murphy 
and Coster 1997). Poor adherence to medication regimens 
contributes to the practice – outcome gap, in which clinical 
guidelines are implemented but expected beneﬁ  ts are not real-
ized. For example, in one study, nonadherence to medication 
was by far the leading cause of hospitalization in a series of 
179 patients admitted to hospital with acute decompensa-
tion of pre-existing heart failure, being implicated in 42% 
of hospital admissions (Michalsen et al 1998). In another 
study of 1,015 outpatients with stable coronary heart disease, 
self-reported medication nonadherence was associated with a 
greater than 2-fold increased rate of subsequent CV events, 
such as coronary heart disease death, myocardial infarction, 
and stroke (Gehi et al 2007).
Multiple medications and complexity of treatment regi-
men are two of the determinants of poor medication adher-
ence. A survey conducted by the National Council on Patient 
Information and Education showed that one-third of patients 
receive at least 2 prescriptions and 10% of patients receive 4 
or more prescriptions after a visit to a primary care physician 
(Dezii 2000). This survey also has estimated that the adher-
ence rate is in the range of 30% for chronic conditions.
There is a clear inverse relationship between complexity 
of the dosing regimen/number of drugs that patients have to 
take and patient adherence. Adherence to antihypertensive 
agents varies inversely with dosing frequency (Sica 1994). 
For example, among 198 Canadian hypertensives randomized 
to diltiazem twice-daily compared with amlodipine once-
daily, those on the once-daily regimen took the medication 
more regularly than those on twice-daily dosing (Leenen et al 
1997). Among 91 diabetic patients using oral antidiabetic 
agents, the adherence rate, deﬁ  ned as the percentage of doses 
taken during the observation period, fell from 79% on once-
daily to 38% on 3-times daily dosing (Paes et al 1997).
Adherence to antihypertensive treatment is inversely 
related to achieved BP levels, ie, nonadherent patients tend 
to have higher BP than adherents. In a prospective study of 
347 hypertensive patients, BP levels were compared between 
adherents and nonadherents with antihypertensive treatment 
(Khalil and Elzubier 1997). Patients were considered adher-
ent if the number of pills prescribed or dispensed – the num-
ber of pills missed/number of pills prescribed or dispensed 
for the interval time × 100 was  80%. BP was signiﬁ  cantly 
lower in adherent than in nonadherent patients.
Adherence rate is also inversely related to the number 
of drugs given. Patients are more adherent when they take 
a combination as a single tablet than if they are given the 
same drugs as 2 separate pills, even when dosed once daily 
(Neutel 2005). A meta-analysis of 9 studies which compared 
ﬁ  xed-dose combinations versus free-drug components of the 
regimen separately for treatment of hypertension (4 studies), 
diabetes (2 studies), tuberculosis (2 studies), and human 
immunodeﬁ  ciency virus (HIV) disease (1 study), showed 
that ﬁ  xed-dose combinations decreased rate of nonadherence 
by 26% compared with free-drug component regimens 
(Bangalore et al 2007). A subgroup analysis of the four studies 
in hypertension showed that ﬁ  xed-dose combinations decreased 
the risk of medication nonadherence by 24% compared with 
free-drug combinations (Figure 2) (Bangalore et al 2007).
Fixed-dose combination therapy is an efﬁ  cacious, rela-
tively safe, and possibly cost-effective method of decreas-
ing BP in most patients with essential hypertension (Sica 
2002). Initiating therapy with more than one agent offers the 
potential advantages of achieving BP control more rapidly 
and avoiding dose-related adverse effects of individual drugs 
by producing greater BP reductions at lower doses of the 
component agents. Fixed-dose combinations also have other 
advantages (Table 1) (Lewanczuk and Tobe 2007; Woodham 
and Oparil 2007).
Adherence to antihypertensive treatment increases with 
ﬁ  xed-dose combinations (Figure 3). Adherence to a ﬁ  xed-
dose combination of the calcium channel blocker (CCB) 
amlodipine with the angiotensin converting-enzyme (ACE) Vascular Health and Risk Management 2008:4(3) 655
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inhibitor benazepril has been compared with adherence to 
free-dose combination therapy of the two agents in a retro-
spective analysis of data obtained from a pharmacy claims 
database in the US (Wanovich and Kerrish 2004). Patients 
who received 2 or more prescriptions for the ﬁ  xed-dose 
combination (n = 2,839) or the two components separately 
(n = 3,367) were identiﬁ  ed and followed up for an average of 
259 days and 247 days, respectively. Adherence to ﬁ  xed-dose 
combination therapy was signiﬁ  cantly greater than for free 
combination therapy, 88% vs 69%, respectively. In another 
study, hypertensive subjects receiving once-daily, single-
capsule, ﬁ  xed-dose combination of amlodipine – benazepril 
Figure 1 Algorithm for treatment of hypertension. BP, blood pressure. Modiﬁ  ed from Chobanian et al (2003).
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demonstrated signiﬁ  cantly better medication adherence than 
subjects receiving an ACE and a CCB as separate compo-
nents, 80.8% vs 73.8%, respectively (Taylor and Shoheiber 
2003). The average annual cost of CV-related care per subject 
was also signiﬁ  cantly lower in hypertensive patients receiv-
ing the ﬁ  xed-dose.
The most important reason for use of combination therapy 
in clinical practice is that combining two antihypertensive 
agents with complementary mechanisms of action produces 
signiﬁ  cantly greater BP reducing efﬁ  cacy than either of the 
components as monotherapy (Chrysant 1994; Chrysant et al 
2004; Hasebe 2005). As hypertension is multifactorial and 
many pathophysiologic factors contribute to high BP, the 
combination of agents with different (and complementary) 
mechanisms of action provides more complete blockade of 
pressor mechanisms with less activation of counter-regulatory 
mechanisms. For example, diuretics activate the renin-
angiotensin-aldosterone system (RAAS), reduce volume, 
and make BP more angiotensin dependent. Concomitant 
administration of an ACE inhibitor or an angiotensin II 
receptor blocker (ARB) blocks angiotensin II generation 
or action, minimizing the compensatory pressor effect of 
diuretic-induced RAAS activation and producing an additive 
BP-lowering effect.
Combination therapy also improves tolerability by reduc-
ing dose-dependent side effects (clinical or metabolic) of 
individual components. Upward dose titration in an attempt 
to avoid the addition of a second agent often leads to increases 
in dose-dependent side effects, resulting in discontinuation of 
therapy. Appropriate combination therapy can also improve 
tolerability if one component can neutralize the adverse 
effects of the second agent. For example, the tendency for 
thiazides to cause hypokalemia is blunted by concomitant use 
of potassium-sparing diuretics, ACE inhibitors, or ARBs. In 
Figure 2 Effect of ﬁ  xed-dose combinations versus free-drug combination on the risk of medication nonadherence in cohort with hypertension. Reprinted from Bangalore S, Kamalakkannan G, 
Parkar S, et al 2007. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 120:713–19. Copyright © 2007, with permission from Elsevier.
Table 1 Advantages of ﬁ  xed-dose combination therapy
  •   Increased compliance, simpliﬁ  ed titration, and convenience 
of use.
 •   Potentiation of antihypertensive effects of single compounds.
 •   Additive or synergistic effects.
 •   Enhancing effect in speciﬁ  c populations.
 •   Attenuation in adverse events.
 •    Decreases in diuretic-induced metabolic changes with ACE 
inhibitors or ARBs.
 •    Decrease in calcium channel anatagonist-related peripheral 
edema with ACE inhibitors or ARB.
 •   Improved overall results, greater BP response, and lower cost.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor 
blocker; BP, blood pressure.Vascular Health and Risk Management 2008:4(3) 657
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a prospective 8-week study of 1,346 hypertensive patients, 
the incidence of hypokalemia was lower in those assigned 
to receive valsartan – hydrochlorothiazide (HCTZ) than in 
those assigned to HCTZ monotherapy (Pool et al 2007). 
Further, the peripheral edema caused by the dihydropyridine 
CCB amlodipine is reduced with ARBs or ACE inhibitors 
(Messerli et al 2000; Neutel et al 2005; Philipp et al 2007). 
For example, in a prospective randomized double-blind 
study of 1,079 hypertensive patients who were assigned to 
receive amlodipine/benazepril or amlodipine or nifedipine 
monotherapy, the incidence of edema was 15% in the high-
dose nifedipine group and 24% in the high-dose amlodipine 
group and was greatly reduced in patients treated with any 
dose of combination therapy (1.5%–3.8%) or low-dose CCB 
(4.9%–5.4%) (Messerli et al 2000). In another prospective 
study of 1,911 patients, the incidence of peripheral edema 
was signiﬁ  cantly lower in patients randomized to receive 
the ARB valsartan plus amlodipine than in patients treated 
with amlodipine monotherapy (5.4% vs 8.7%, respectively; 
p = 0.014) (Philipp et al 2007).
Overview of currently available 
ﬁ  xed combinations
The very earliest outcome trial of antihypertensive therapy, 
the Veteran’s Administration Cooperative Study on Antihy-
pertensive Agents, demonstrated dramatic reductions in CV 
outcomes with a triple combination of HCTZ, reserpine, and 
hydralazine compared with placebo (Veterans Administra-
tion Cooperative Study 1967). Fixed-dose combinations of 
newer antihypertensive drugs have been developed in recent 
years, in response to the realization that most patients require 
multiple antihypertensive agents for BP control (Prisant et al 
1995). The currently available ﬁ  xed-combination therapies 
are listed in Table 2.
ACE inhibitor – diuretic or ARB – diuretic combina-
tions are the most commonly used ﬁ  xed-dose combination 
antihypertensive agents because of an additive effect on BP 
reduction related to complementary mechanisms of action 
of the components and the favorable vascular, metabolic, 
cardiac, and renoprotective effects of the ACE inhibitors and 
ARBs (Lewis et al 1993; Weir and Dzau 2001; Chobanian 
et al 2003). Randomized controlled clinical trials that com-
pared the combination versus monotherapy with either ACE 
inhibitor or HCTZ have generally demonstrated greater 
BP-lowering efﬁ  cacy with low-dose combinations over 
higher-dose monotherapy with either single agent. In a 
representative trial, patients were randomized to 8 weeks of 
placebo, lisinopril 10 mg, HCTZ 12.5 mg, HCTZ 25 mg, or 
combination therapy with lisinopril 10 mg and either HCTZ 
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Figure 3 Medication adherence with combination of amlodipine/benazepril single-
tablet compared to same combination as separate components.
Table 2 Currently available combination antihypertensives in US 
in 2007
ACE inhibitors and diuretics
  Benazepril – HCTZ
  Captopril – HCTZ
  Enalapril – HCTZ
  Lisinopril – HCTZ
  Fosinopril – HCTZ
  Quinapril – HCTZ
  Moexipril – HCTZ
ARBs and diuretics
  Losartan – HCTZ
  Valsartan – HCTZ
  Irbesartan – HCTZ
  Telmisartan – HCTZ
  Olmesartan – HCTZ
  Candesartan – HCTZ
  Eprosartan – HCTZ
Potassium-sparing diuretics and HCTZ
  Amiloride – HCTZ
  Spironolactone – HCTZ
  Triamterene – HCTZ
BBs and diuretics
  Metoprolol – HCTZ
  Timolol – HCTZ
  Atenolol – Chlorthalidone
  Bisoprolol – HCTZ
  Nadolol – Bendroﬂ  umethiazide
  Propranolol – HCTZ
ACE inhibitors and CCB
  Enalapril – Diltiazem
 Benazepril  –  Amlodipine
  Enalapril – Felodipine
 Trandolapril  –  Verapamil
ARBs and CCBs
 Valsartan  –  Amlodipine
 Olmesartan  –  Amlodipine
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor 
blocker; BB, β-blockers; CCB, calcium-channel blockers; HCTZ, hydrochlorothiazide.Vascular Health and Risk Management 2008:4(3) 658
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12.5 mg or 25 mg (Chrysant 1994). Monotherapy with either 
agent lowered DBP by 6–8 mmHg over placebo, and com-
bination therapy produced a further 6–7 mmHg reduction 
in DBP. BP response rate, deﬁ  ned as a decrease in DBP of 
 10 mmHg or achieving a goal of  90 mmHg, was higher 
with combination therapy (70%–80%) than with lisinopril 
or HCTZ monotherapy (40%–50%).
Similarly, studies of ARB – diuretic combinations have 
demonstrated signiﬁ  cantly greater reductions in SBP and 
DBP compared with monotherapy with either individual 
agent. A representative factorial study evaluated the efﬁ  cacy 
of regimens that included either olmesartan 10–40 mg a day, 
HCTZ 12.5 or 25 mg a day, placebo, or the combination of 
olmesartam and HCTZ (Chrysant et al 2004). The greatest 
effect on BP was noted in the arm receiving 40 mg of 
olmesartan and 25 mg of HCTZ, in which SBP decreased by 
23.5 mmHg and DBP by 13.7 mmHg more than with placebo 
(Figure 4). The addition of diuretic to placebo or to any dose 
of olmesartan produced an additional BP response compared 
with placebo or olmesartan alone. Control ( 140/90 mmHg) 
rates were greater in patients taking the highest dose of the 
combined agents than in those taking the highest doses of 
monotherapies.
ACE inhibitor – CCB combinations also have additive 
antihypertensive effects and offer the added advantage of 
minimizing adverse effects of individual components (eg, edema 
with dihydropyridine CCBs). The Anglo-Scandinavian Cardiac 
Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-
BPLA) presented evidence that a CCB – ACE inhibitor 
combination is more effective in lowering BP and reducing risk 
of mortality and major CV events than traditional therapy with 
a β-blocker (BB) – thiazide combination (Dahlöf et al 2005; 
Poulter et al 2005). ASCOT included 19,257 hypertensive 
patients randomly assigned to either amlodipine-based treatment 
(with the option of adding perindopril) or to atenolol-based 
treatment (with the option of adding bendroﬂ  umethiazide). 
BP control was deﬁ  ned as  140/90 mmHg in patients without 
diabetes and  130/80 mmHg with diabetes. The CCB – ACE 
inhibitor combination lowered BP by an average of 2.7/1.9 
mmHg more than the BB – diuretic combination throughout the 
5.5 year median follow-up period. Signiﬁ  cant reductions in a 
number of outcomes (all-cause mortality, nonfatal myocardial 
infarction, and new-onset diabetes) were noted with CCB – ACE 
inhibitor compared with BB – diuretic. Importantly, by the 
end of the trial only 15% and 9% of participants were taking 
amlodipine or atenolol monotherapy, respectively, providing 
additional evidence for the inadequacy of monotherapy for 
BP control.
Similar to the ACE inhibitor – CCB combination, 
ARB – CCB combinations have showed efﬁ  cacy in reducing 
BP. The Nifedipine and Candesartan Combination Study 
(NICE Combi) randomized 258 hypertensive patients to 
receive controlled-release nifedipine 20 mg plus candesartan 
8 mg in combination or up-titration of candesartan 
12 mg monotherapy (Hasebe et al 2005). BP reduction 
was signiﬁ  cantly greater in the combination therapy group 
(12.1/8.7) than in the up-titrated monotherapy group (4.1/4.6, 
p   0.0001) after 8 weeks of follow-up. The NICE Combi 
study provides additional evidence that low-dose fixed 
combination therapy is more effective in reducing BP than 
monotherapy in high-dose.
ACE inhibitor – CCB combination therapy has become 
widely used due to high efﬁ  cacy in reducing BP and high 
tolerability. Evidence that both CCBs and ACE inhibitors 
have beneficial effects on endothelial function (Taddei 
et al 2000) has also led to the hypothesis that, for the same 
BP effects, an ACE inhibitor – CCB combination may 
have outcome advantages over an ACE inhibitor – diuretic 
combination. Further, it has been hypothesized that the 
neutral metabolic effects of amlodipine, in contrast to the 
adverse metabolic effects of diuretics, translate into better 
clinical outcomes, even when each agent is combined with 
an ACE inhibitor. The latter argument has provided the 
rationale for the Avoiding Cardiovascular events through 
COMbination therapy in Patients Living with Systolic 
Hypertension (ACCOMPLISH) trial, the ﬁ  rst randomized 
controlled blinded study to compare prospectively the 
effects of 2 ﬁ  xed combinations of antihypertensive drugs, 
benazepril – amlodipine and benazepril – HCTZ on CV 
disease outcomes in high-risk hypertensive patients (Jamerson 
et al 2004). The primary study endpoint is a composite of 
CV mortality and morbidity and the secondary endpoints 
include new onset diabetes, progression of renal disease, and 
hospitalization for congestive heart failure. Early unblinded 
results from 10,704 participants from both treatment groups 
combined have shown higher BP control rates compared with 
previous clinical trials (Jamerson et al 2007). The 6-month 
BP control rate ( 140/90 mmHg) was 73% in the overall 
trial (78% in the US); 43% of diabetics and 40% of patients 
with renal disease achieved the more aggressive BP goal of 
 130/80 mmHg. Serious hypotensive events occurred in only 
1.8%, suggesting that these combinations are appropriate 
and safe for hypertensive patients who are at high-risk. 
Final results of ACCOMPLISH will provide insight into 
whether CCB – RAAS inhibitor combination therapy offers 
advantages over diuretic-RAAS inhibitor combinations in Vascular Health and Risk Management 2008:4(3) 659
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lowering BP, minimizing adverse effects, and preventing 
morbid and mortal CV events.
Amlodipine
Pharmacology
Dihydropyridine CCBs act by decreasing Ca2+ entry to cells 
through the L-type Ca2+ channel (Krum 1997; Messerli 2003). 
Decreased availability of intracellular Ca2+ in arterial smooth 
muscle cells prevents actin and myosin from interacting, 
resulting in vasodilation (Prisant 2005). Dihydropiridine 
CCBs also facilitate natriuresis by increasing renal blood 
ﬂ  ow, dilating afferent arterioles, and increasing glomerular 
ﬁ  ltration pressure.
Amlodipine is a long-acting third generation 
dihydropyridine CCB that is the most commonly used agent 
in its class for the treatment of hypertension (Abernethy and 
Schwartz 1999; Basile 2004). More than 90% of amlodipine 
is absorbed and 95% of circulating amlodipine is bound to 
plasma proteins. It does not have an extensive hepatic ﬁ  rst-
pass metabolism, which contributes to its prolonged effect. 
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The time to peak effect of amlodipine is 10–14 hours; its 
elimination half-life is 35–45 hours and steady-state plasma 
levels are reached after 7–8 days of consecutive daily dosing 
(Prisant 2005). About 90% of amlodipine is converted to 
inactive metabolites via hepatic metabolism, and 60% of 
the metabolites are excreted in the urine. In patients with 
chronic kidney disease, the pharmacokinetics of amlodipine 
are minimally changed. In hepatic disease, diminished 
systemic clearance may necessitate dosage adjustments. 
Aging slows the metabolism of amlodipine, presumably 
secondary to the accompanying decrease in hepatic blood 
ﬂ  ow, sometimes necessitating dosage adjustments in the 
elderly (Prisant 2005; Weir 2008). Amlodipine may cause 
reﬂ  ex tachycardia early in the course of therapy or at 
very high doses, but this sympathoexcitatory effect is not 
evident with usual clinical doses or with long term treatment 
(Weir 2008).
Efﬁ  cacy and safety
Amlodipine effectively lowers BP and is also effective in 
reducing CV disease outcomes, both morbid and mortal, 
with the exception of heart failure. In the Antihypertensive 
and Lipid-Lowering Treatment to Prevent Heart Attack Trial 
(ALLHAT), more than 40,000 high risk hypertensive patients 
were randomly assigned to receive chlorthalidone, amlodip-
ine, lisinopril, or doxazosin (ALLHAT 2002). Participants 
were men and women aged 55 years or older who had stage 
1 or stage 2 hypertension with at least 1 additional risk fac-
tor for coronary heart disease events. ALLHAT tested the 
hypothesis that the newer drug classes (CCBs, ACE inhibi-
tors, α-blockers) are superior to the thiazide-like diuretics in 
preventing fatal and nonfatal coronary events. Thus, due to 
the design of the trial, the effects of a RAAS inhibitor-CCB 
combination could not be tested. ALLHAT is the only large 
outcome trial in hypertension that has included a racially/
ethnically diverse patient population (35% Black, 19% His-
panic) and a large (36%) population of diabetics. Amlodipine 
was as effective as chlorthalidone in reducing the primary 
combined endpoint of fatal coronary heart disease or nonfatal 
myocardial infarction. In addition, amlodipine was effective 
in reducing combined coronary heart disease events and end-
stage renal disease. However, incidence of heart failure was 
38% higher in patients assigned to amlodipine than patients 
assigned to chlorthalidone in the absence of concomitant 
RAAS inhibitor therapy in either group. There was no sig-
niﬁ  cant difference in adverse effects between amlodipine and 
chlorthalidone based therapy, refuting previous claims that 
dihydropyridine CCBs precipitate coronary events.
The Valsartan Antihypertensive Long-Term Use 
Evaluation (VALUE) trial compared the effects of amlodipine 
and valsartan as ﬁ  rst-line therapy in reducing CV outcomes 
in hypertensive patients at high CV risk (Julius et al 2004). 
Amlodipine treatment was associated with a more prompt and 
robust reduction in BP than valsartan treatment, particularly 
early in the trial when participants were on monotherapy. In 
the study as a whole, amlodipine treatment was associated with 
a signiﬁ  cantly greater reduction in the incidence of nonfatal 
myocardial infarction compared with valsartan treatment. 
Subanalysis of VALUE results reported that patients treated 
with amlodipine monotherapy had a 22% higher risk of 
heart failure than those treated with valsartan monotherapy; 
there were no other signiﬁ  cant outcome differences (Julius 
et al 2006). These data are consistent with the ﬁ  ndings in 
ALLHAT that amlodipine does not prevent heart failure as 
effectively as some other antihypertensive drugs. However, 
data from Prospective Randomized Amlodipine Survival 
Evaluation (PRAISE) study showed that amlodipine does not 
increase CV morbidity or mortality in patients with severe 
heart failure, suggesting that this CCB does not worsen 
established heart failure (Packer et al 1996).
In ASCOT, the amlodipine – perindopril regimen was 
more effective in reducing BP and preventing CV events 
than the atenolol – bendroﬂ  umethiazide regimen (Dahlöf 
et al 2005). BP was, on average, 2.7/1.9 mmHg lower in the 
amlodipine group than in the atenolol group during 5.7 years 
of follow-up. Amlodipine ± perindopril was also superior 
in preventing fatal and nonfatal stroke, total CV events and 
procedures, and all-cause mortality than atenolol ± ben-
droﬂ  umethiazide. Interestingly, the incidence of fatal and 
nonfatal heart failure did not differ between amlodipine- and 
atenolol-based regimens, suggesting that blocking the RAAS 
neutralizes the adverse effects of amlodipine monotherapy. 
By the end of the trial, 85% of patients assigned to amlo-
dipine and 91% of those assigned to atenolol were taking at 
least 2 antihypertensive agents, reinforcing the concept that 
combination therapy is needed to control BP in high risk 
hypertensive patients. There was a signiﬁ  cant difference in 
favor of the amlodipine-based regimen in the proportion of 
patients who stopped the trial therapy because of serious 
adverse events.
Amlodipine has been proven effective in decreasing 
left ventricular mass in hypertensive patients. In a 1-year 
prospective study of 59 patients with diastolic hypertension 
who were randomized to lisinopril or amlodipine, amlodipine 
decreased left ventricular mass as effectively as lisinopril 
(–11.0 g/m2 vs –12.6 g/m2, respectively) (Beltman et al 1988). Vascular Health and Risk Management 2008:4(3) 661
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Further, in the Effects of Amlodipine and Lisinopril on Left 
Ventricular Mass and Diastolic Function (ELVERA) trial, 
which compared amlodipine with lisinopril therapy in 166 
elderly patients with hypertension (95–115/160–220 mmHg), 
amlodipine and lisinopril reduced left ventricular mass and 
improved diastolic function to a similar extent after 2 years 
of follow-up (Terpstra et al 2001).
Olmesartan
Pharmacology
ARBs lower BP by selectively blocking the binding 
of angiotensin II to the AT1 receptor in vascular smooth 
muscle and other cell types (Ruddy and Kostis 2005). 
Olmesartan medoxomil, the most recently developed ARB, 
is rapidly and completely bioactivated by ester hydrolysis 
in the gut wall to the pharmacologically active compound 
olmesartan, with peak plasma concentrations achieved 
between 1 and 3 hours and an elimination half-life of 
12–18 hours (Laeis et al 2001; Schwocho and Masonson 
2001). The absolute bioavailability of olmesartan medoxomil 
after oral administration is 26%–28.6%. Steady-state plasma 
concentrations are reached within the ﬁ  rst few days, and 
accumulation is not noted on long-term dosing. Olmesartan 
is not metabolized; 35%–50% of the systemically available 
active compound is excreted unchanged in the urine and the 
remainder in the bile. Olmesartan medoxomil has minimal 
or no inhibitory activity on human cytochrome p450 (Laeis 
et al 2001; Schwocho and Masonson 2001). Olmesartan 
has a unique mechanism of binding to the AT1 receptor 
that appears to contribute to its sustained duration of AT1 
receptor blockade (Miura et al 2006, 2008). This involves 
the “double chain domain”, whereby olmesartan binds to 
the receptor at 2 sites, a –OH group and an α-COOH group, 
whereas other ARBs bind only at the –OH group. It has been 
shown that olmesartan produces more sustained inhibition of 
the pressor effects of infused angiotensin than other ARBs in 
normotensive adults, suggesting a more prolonged blockade 
of the AT1 receptor. It has been hypothesized (but not proven) 
that this sustained pressor inhibition is a function of the 
“double chain domain” binding.
Efﬁ  cacy and safety
Olmesartan reduces BP rapidly and effectively in hyperten-
sive patients. An analysis of 7 randomized, double-blind, 
placebo-controlled, parallel-group studies compared the 
safety and efﬁ  cacy of olmesartan monotherapy with pla-
cebo in patients with essential hypertension (Neutel 2001). 
Olmesartan produced dose-dependent BP reductions in both 
DBP and SBP within 1 week of initiating treatment, and the 
response was nearly maximal within 2 weeks.
At traditionally recommended starting doses, olmesartan 
reduces BP more effectively than other ARBs (Oparil et al 
2005). A 588 patient, multicenter, randomized, double-blind, 
trial that compared once-a-day therapy with the recom-
mended starting doses of losartan, valsartan, and irbesartan 
showed a signiﬁ  cantly greater reduction in sitting cuff DBP 
at trough with olmesartan (11.5 mmHg) than with losartan, 
valsartan, and irbesartan (8.2, 7.9, and 9.9 mmHg, respec-
tively, p   0.005 olmesartan vs losartan; p   0.05 olmesartan 
vs valsartan and irbesartan) (Oparil et al 2001). Reductions in 
cuff SBP with the four ARBs had the same numerical trend, 
but differences between treatments were not statistically sig-
niﬁ  cant due to variability in the data. The reduction in mean 
24-hour DBP with olmesartan (8.5 mmHg) was signiﬁ  cantly 
greater than reductions with losartan and valsartan (6.2 and 
5.6 mmHg, respectively, p   0.05) and showed a trend toward 
signiﬁ  cance compared with the reduction in DBP with irbe-
sartan (7.4 mmHg; p = 0.087). The reduction in mean 24-hour 
SBP with olmesartan (12.5 mmHg) was signiﬁ  cantly greater 
than those with losartan and valsartan (9.0 and 8.1 mmHg, 
respectively) and equivalent to the reduction with irbesartan 
(11.3 mmHg). All drugs were well tolerated.
The differences in BP reduction with olmesartan com-
pared with other ARBs are attenuated at higher doses. In an 
12-week, randomized, double-blind, forced titration study, 
723 hypertensive patients were assigned to receive olmesar-
tan, losartan, and valsartan (Giles et al 2007). Patients were 
randomized to olmesartan 20 mg, losartan 50 mg, valsartan 
80 mg, or placebo, all once daily. Doses were titrated to 40, 
100, and 160 mg once daily for olmesartan, losartan, and 
valsartan, respectively, after 4 weeks of treatment. At week 8, 
doses were titrated to 50 mg twice daily for losartan and 
320 mg once daily for valsartan; olmesartan remained at the 
maximum recommended dose of 40 mg once daily. All three 
medications signiﬁ  cantly reduced mean seated DBP from 
baseline compared with placebo. At week 8, patients receiv-
ing olmesartan 40 mg once daily had signiﬁ  cantly greater 
reductions in mean seated DBP than those receiving losartan 
(–15.2/–12.9 vs –10.9/-9.4 mmHg, respectively, p   0.001); 
there was no signiﬁ  cant difference compared with valsartan. 
A signiﬁ  cantly greater percentage of patients achieved BP 
goals ( 140/90 mmHg) with olmesartan compared with 
losartan and valsartan (39.7, 19.8, and 29.0%, respectively, 
p   0.001 vs losartan and p = 0.031 vs valsartan).
Olmesartan has vasoprotective and antiinflammatory 
effects that are unrelated to BP reduction. In the EUropean Vascular Health and Risk Management 2008:4(3) 662
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Trial on Olmesartan and Pravastatin in Inflammation 
and Atherosclerosis (EUTOPIA) study, investigators 
compared the antiinflammatory effects of olmesartan 
alone and with pravastatin in patients with essential 
hypertension and microinflammation (Fliser et al 2004). 
Olmesartan treatment significantly reduced serum levels 
of high-sensitivity C-reactive protein (CRP), high-sensi-
tivity tumor necrosis factor-alpha (TNF-α), interleukin-6 
(IL-6), and monocyte chemotactic protein-1 (MCP-1) 
compared to placebo independently of BP reduction. 
Treatment with pravastatin alone did not significantly 
alter inflammation markers. The Vascular Improvement 
with Olmesartan medoxomil Study (VIOS) tested the 
hypothesis that suppression of RAAS with olmesartan 
reverses abnormal remodeling of resistance vessels and 
has favorable effects on central hemodynamics compared 
to suppression of sympathetic drive with the BB atenolol 
despite equivalent BP control (Smith et al 2007). In the 
presence of nearly physiological BP control, olmesartan 
reversed small resistance vessel remodeling virtually 
back to normal, while atenolol had little to no effect on 
the vascular wall. Further, olmesartan, but not atenolol, 
reduced the augmentation index. Thus, olmesartan has 
favorable effects on surrogate endpoints, but results of 
outcome trials are not yet available.
Olmesartan – amlodipine 
combination
Pharmacology
The pharmacokinetics of the olmesartan – amlodipine combi-
nation are equivalent to the pharmacokinetics of amlodipine 
and olmesartan medoxomil administered separately (Haworth 
et al 2007a; Rohatagi et al 2007; Salazar et al 2007). The 
bioavailability of the combination is well below 100%, and 
is not affected by food (Haworth et al 2007b).
Efﬁ  cacy and safety
The combination of olmesartan and amlodipine in a single 
tablet effectively reduces BP and attenuates the adverse 
events of the amlodipine component in hypertensive patients. 
An 8-week, multi-center, double-blind, randomized, placebo-
controlled, parallel-group, factorial study of 1,940 subjects 
with mild to severe hypertension (seated DBP ranging from 
99 to 120 mmHg) compared BP responses with placebo, 
monotherapy with amlodipine 5 mg or 10 mg, with olmes-
artan medoxomil 10, 20, or 40 mg, and combination therapy 
with amlodipine – olmesartan medoxomil at doses of 5/10, 
5/20, 5/40, 10/10, 10/20, and 10/40 mg (Chrysant et al 2007). 
All combinations produced greater mean reductions in BP 
than either drug alone. The highest dose combination, amlo-
dipine 10 mg plus olmesartan 40 mg, reduced SBP by 30.1 
mmHg, a 53% greater reduction than with 10 mg amlodipine 
alone. DBP was reduced by 19 mmHg, compared with 12.7 
mmHg for amlodipine alone. Addition of olmesartan to 
amlodipine decreased the amlodipine-related adverse effects. 
All combinations of amlodipine 10 mg with olmesartan 
demonstrated less peripheral edema than amlodipine 10 mg 
monotherapy.
Patient perspective
Although recent guidelines and advisory statements are 
recommending lower thresholds and goals for antihyper-
tensive treatment, approximately two-thirds of patients 
do not achieve the goals. Population characteristics, 
such as increased life expectancy, higher obesity rates, 
and decreased physical activity, as well as provider 
characteristics, including inadequate attention to SBP 
elevations and the more aggressive BP goals recom-
mended by recent guidelines, are factors that predispose 
to antihypertensive treatment resistance. For patients with 
difﬁ  cult-to-control hypertension, the ﬁ  xed-dose combina-
tion offers many advantages, such as convenience of use, 
fewer adverse events, greater antihypertensive potency, 
and lower cost.
Conclusions
Combination therapy is recommended by treatment guide-
lines and has become widely accepted by health care provid-
ers for the therapy of hypertension. Fixed-dose combinations 
provide effective antihypertensive treatment by achieving 
BP goals more frequently, improving patient adherence, and 
decreasing adverse effects.
Use of effective combination therapies blocks two or 
more BP regulatory systems, thus providing more effective 
and more physiologic reduction in BP than most monothera-
pies. Outcomes studies support inclusion of ARBs, such as 
olmesartan, and CCBs, such as amlodipine, in antihyperten-
sive drug regimens.
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